{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dementia+Alzheimers&page=6",
    "query": {
      "condition": "Dementia Alzheimers",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 2080,
    "total_pages": 208,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dementia+Alzheimers&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dementia+Alzheimers&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T13:36:10.511Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03393520",
      "title": "Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation in Patients With Dementia of the Alzheimer's Type"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AVP-786",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 601,
      "start_date": "2017-10-13",
      "completion_date": "2023-12-14",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 93,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03393520"
    },
    {
      "nct_id": "NCT00626210",
      "title": "Modafinil Treatment for Sleep/Wake Disturbances in Older Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Insomnia",
        "Sleep Initiation and Maintenance Disorders",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "modafinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Palo Alto Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2008-02",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2019-10-28",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00626210"
    },
    {
      "nct_id": "NCT01855360",
      "title": "Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyloidosis; Heart (Manifestation)",
        "Senile Cardiac Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Tauroursodeoxycholic Acid and Doxycycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-06",
      "completion_date": "2015-05-31",
      "has_results": true,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01855360"
    },
    {
      "nct_id": "NCT05518968",
      "title": "Videoconferencing Acceptance and Commitment Therapy With a Web App Use for Family Caregivers of People With Dementia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Acceptance and commitment therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-01-01",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05518968"
    },
    {
      "nct_id": "NCT02176226",
      "title": "IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Anxiety Disorders"
      ],
      "interventions": [
        {
          "name": "IntelliCare",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2015-03",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2023-04-26",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176226"
    },
    {
      "nct_id": "NCT00478491",
      "title": "fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Magnetic Resonance Imaging",
        "Alzheimer's Disease",
        "Dementia",
        "Adult Children",
        "Risk"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 390,
      "start_date": "2003-01",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2016-10-27",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00478491"
    },
    {
      "nct_id": "NCT00000176",
      "title": "Alzheimer's Disease Prevention Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Memory Disorders"
      ],
      "interventions": [
        {
          "name": "Estrogen",
          "type": "DRUG"
        },
        {
          "name": "Estrogen and Progesterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "65 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2010-11-05",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Irvine, California • Stamford, Connecticut + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000176"
    },
    {
      "nct_id": "NCT06489548",
      "title": "Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia",
        "Alzheimers Disease",
        "Mild Cognitive Impairment Due to Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Foralumab TZLS-401 50 µg",
          "type": "DRUG"
        },
        {
          "name": "Foralumab TZLS-401 100 µg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2025-09-16",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06489548"
    },
    {
      "nct_id": "NCT06923501",
      "title": "Evaluation of a Mobile App Program for Coping With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Tools for Coping with Cancer Calm Health mobile app program",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-06-11",
      "completion_date": "2027-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06923501"
    },
    {
      "nct_id": "NCT05291234",
      "title": "A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease (AD)"
      ],
      "interventions": [
        {
          "name": "ABBV-916",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 106,
      "start_date": "2022-08-15",
      "completion_date": "2025-11-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-04T13:36:10.511Z",
      "location_count": 32,
      "location_summary": "Tucson, Arizona • Irvine, California • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05291234"
    }
  ]
}